Endothelin-1 Levels in Heart Failure Track Disease Severity and Predict Outcomes
Plasma endothelin-1 correlated with NYHA class, exercise capacity, BNP, and predicted adverse outcomes in chronic heart failure, supporting its role as a complementary biomarker to natriuretic peptides.
Quick Facts
What This Study Found
Plasma ET-1 correlated with NYHA class, exercise capacity, and BNP in CHF patients, and independently predicted adverse outcomes, providing complementary prognostic information to natriuretic peptides.
Key Numbers
How They Did This
Cross-sectional study measuring plasma ET-1, BNP, ANP, and clinical parameters (NYHA class, peak VO2, echocardiography) in chronic heart failure patients with outcome follow-up.
Why This Research Matters
ET-1 captures vascular dysfunction that BNP doesn't. Together, they provide a more complete picture of heart failure severity and prognosis than either alone.
The Bigger Picture
Heart failure involves both cardiac pump failure (BNP) and vascular dysfunction (ET-1). Measuring both captures the full pathophysiology for optimal risk stratification.
What This Study Doesn't Tell Us
Cross-sectional with outcome follow-up. Specific ET-1 cutoffs for clinical decisions not established. ET-1 assay variability is a concern.
Questions This Raises
- ?Should ET-1 be routinely measured alongside BNP in heart failure?
- ?Does ET-1-guided therapy improve outcomes?
- ?Can endothelin antagonists improve vascular dysfunction in heart failure?
Trust & Context
- Key Stat:
- Beyond BNP ET-1 independently predicted adverse outcomes in heart failure even after accounting for BNP — it captures vascular disease that BNP doesn't measure
- Evidence Grade:
- Moderate evidence from a clinical study with multi-parameter correlation and outcome prediction.
- Study Age:
- Published in 2003. Endothelin in heart failure is well-established, though endothelin antagonists have had mixed clinical results in chronic HF.
- Original Title:
- Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure.
- Published In:
- Journal of cardiac failure, 9(4), 318-24 (2003)
- Authors:
- Kinugawa, Toru, Kato, Masahiko, Ogino, Kazuhide, Osaki, Shuichi, Igawa, Osamu, Hisatome, Ichiro, Shigemasa, Chiaki
- Database ID:
- RPEP-00836
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
What does endothelin-1 tell us about heart failure?
ET-1 reflects vascular constriction and damage — the blood vessel component of heart failure. BNP reflects heart muscle stress. Together they show both the heart and vessel sides of the disease.
Should this be part of routine testing?
This study supports adding ET-1 to BNP for more complete heart failure assessment, especially for predicting vascular complications and exercise intolerance.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00836APA
Kinugawa, Toru; Kato, Masahiko; Ogino, Kazuhide; Osaki, Shuichi; Igawa, Osamu; Hisatome, Ichiro; Shigemasa, Chiaki. (2003). Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure.. Journal of cardiac failure, 9(4), 318-24.
MLA
Kinugawa, Toru, et al. "Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure.." Journal of cardiac failure, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Plasma endothelin-1 levels and clinical correlates in patien..." RPEP-00836. Retrieved from https://rethinkpeptides.com/research/kinugawa-2003-plasma-endothelin1-levels-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.